Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Next Previous
Trial Profile

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fezagepras (Primary)
  • Indications Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Liminal BioSciences

Most Recent Events

  • 14 Jun 2019 According to a ProMetic Life Sciences media release, data demonstrating that PBI-4050 reduced biomarkers associated with kidney injury from this study along with results from cellular and animal models of acute and chronic kidney injuries will be presented in an oral presentation at the 56th Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) (on 14th Jun 2019).
  • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
  • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top